Drug Trial Radar · NCT00141960
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
Last checked: Nov 19, 2026Latest source record: Nov 21, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
480
Actual
Start
Sep 2005
Primary completion
Not stated
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Sep 2, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Gastroesophageal reflux disease (GERD) considered to be associated with mucosal damages in the esophagus and heartburn, which may sometimes interfere with daily activities due likely to reflux of acid gastric contents. While most of the patients given the diagnosis of GERD do not exhibit endoscopically obvious impairment in esophageal mucous membrane, they have subjective symptoms of non-erosive GERD including heartburn. But no drug has been launched in Japan, which targets non-erosive GERD. This study will examine the efficacy and safety of famotidine in subjects with non-erosive GERD.
Conditions
- Gastroesophageal Reflux
Interventions
FamotidineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of days with no heart burn in the treatment period
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Hokkaido Region, Japan
Site not named
Kanto Region, Japan
Site not named
Kinki Region, Japan
Site not named
Kyushu Region, Japan
Site not named
Shikoku Region, Japan
Site not named
Tohoku Region, Japan
Site not named
Tokai Region, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.